Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of hypertension and cardiovascular diseases
3.2.1.2 Increasing aging population
3.2.1.3 Growing awareness and screening programs
3.2.1.4 Innovations in drug delivery
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects and safety concerns
3.2.2.2 Alternative treatment options
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Dosage, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Tablet
5.3 Liquid
Chapter 6 Market Estimates and Forecast, By Dosage Strength, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 10 Mg
6.3 20 Mg
6.4 25 Mg
Chapter 7 Market Estimates and Forecast, By Patient Age Group, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Children
7.3 Adults
Chapter 8 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hypertension
8.3 Heart failure
8.4 Heart attack
8.5 Diabetic kidney disease
8.6 Other applications
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacy
9.3 Retail pharmacy
9.4 Online pharmacy
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East and Africa
10.6.1 Saudi Arabia
10.6.2 South Africa
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 AbbVie Inc.
11.2 Amneal Pharmaceutical, Inc.
11.3 AstraZeneca
11.4 Apotex Inc.
11.5 Aurobindo Pharma Ltd.
11.6 Bausch Health Companies, Inc.
11.7 Cipla Limited
11.8 Hikma Pharmaceutical PLC.
11.9 Lupin Limited
11.10 Merck & Co., Inc.
11.11 Pfizer Inc.
11.12 Sun Pharmaceutical Industries Limited
11.13 Teva Pharmaceutical Industries Limited
11.14 Vitaris Inc.
11.15 Zydus Lifesciences Limited
